Uricase Inhibitors
1 drugsAbout Uricase
Uricase, or urate oxidase, is an enzyme that catalyzes uric acid oxidation into allantoin, crucial for purine metabolism in many species but absent in humans. This conversion facilitates uric acid excretion by transforming it into the more soluble allantoin.
The absence of functional uricase in humans leads to hyperuricemia and gout, making it a therapeutic target for managing these conditions. Currently, there is no genetic evidence available to support uricase as a drug target.
Uricase is targeted by one FDA-approved biologic drug, KRYSTEXXA, developed by Horizon Pharma, for gout treatment. Further research could expand therapeutic options in this area.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Endometrial Cancer with only 1 trials.
Top Drugs
Horizon Pharma is the only company with an approved drug targeting uricase.
High market concentration suggests significant entry barriers or limited investment in this target.
Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Uricase, using enzyme modality.
The absence of small molecule or antibody drugs indicates a whitespace opportunity for novel modalities.
Clinical Trials 40 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 12 | 11 | 0 | 1 | 100% |
| Phase 2 | 9 | 8 | 1 | 0 | 89% |
| Phase 3 | 9 | 7 | 0 | 2 | 100% |
| Phase 4 | 10 | 8 | 1 | 1 | 89% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Phase 3 Readout Calendar Pro
1 Phase 3 trial testing approved Uricase drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting Uricase. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
Drug Approval Timeline (2010 - 2010)
The first and only drug, KRYSTEXXA, was approved in 2010.
The lack of recent approvals suggests potential saturation or challenges in developing new uricase-targeting therapies.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (12 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 19 clinical trials targeting Uricase.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities